tbuckley/cabot-search huggingface dataset:
Sustained release of endothelial progenitor cell-derived extracellular vesicles from shear-thinning hydrogels improves angiogenesis and promotes function after myocardial infarction
Authors: Carol W Chen, Leo L Wang, Samir Zaman, Jon Gordon, Maria F Arisi, Chantel M Venkataraman, Jennifer J Chung, George Hung, Ann C Gaffey, Lynn A Spruce, Hossein Fazelinia, Robert C Gorman, Steven H Seeholzer, Jason A Burdick, Pavan Atluri
Journal: Cardiovascular Research (2018)

Previous studies have demonstrated improved cardiac function following myocardial infarction (MI) after administration of endothelial progenitor cells (EPCs) into ischaemic myocardium. A growing body of literature supports paracrine effectors, including extracellular vesicles (EVs), as the main mediators of the therapeutic benefits of EPCs. The direct use of paracrine factors is an attractive strategy that harnesses the effects of cell therapy without concerns of cell engraftment or viability. We aim to reproduce the beneficial effects of EPC treatment through delivery of EPC-derived EVs within a shear-thinning gel (STG) for precise localization and sustained delivery. EVs were harvested from EPCs isolated from adult male Rattus norvegicus (Wistar) rats and characterized by electron microscopy, nanoparticle tracking analysis (NTA), and mass spectrometry. EVs were incorporated into the STG and injected at the border zone in rat models of MI. Haemodynamic function, angiogenesis, and myocardial remodelling were analyzed in five groups: phosphate buffered saline (PBS) control, STG control, EVs in PBS, EVs in STG, and EPCs in STG. Electron microscopy and NTA of EVs showed uniform particles of 50–200 nm. EV content analysis revealed several key angiogenic mediators. EV uptake by endothelial cells was confirmed and followed by robust therapeutic angiogenesis. In vivo animal experiments demonstrated that delivery of EVs within the STG resulted in increased peri-infarct vascular proliferation, preservation of ventricular geometry, and improved haemodynamic function post-MI. EPC-derived EVs delivered into ischaemic myocardium via an injectable hydrogel enhanced peri-infarct angiogenesis and myocardial haemodynamics in a rat model of MI. The STG greatly increased therapeutic efficiency and efficacy of EV-mediated myocardial preservation.
More than the tip of the iceberg: association between disabilities and inability to attend a clinic-based post-ICU follow-up and how it may impact on health inequalities
Authors: Regis Goulart Rosa, Renata Kochhann, Paula Berto, Livia Biason, Juçara Gasparetto Maccari, Patrícia De Leon, Francine Dutra, Sâmia Faria da Silva, Daniel Sganzerla, Daniel Schneider, Paulo Ricardo Cardoso, Frederico Klein Gomes, Vitória Homem Machado, Gregory Medeiros, Tulio Frederico Tonietto, Luciana Tagliari, Mariana Mattioni, Luisa Anzolin, Maicon Oliveira, Juliana Mara Stormovski de Andrade, Maicon Falavigna, Caroline Cabral Robinson, Cassiano Teixeira
Journal: Intensive Care Medicine (2018)
CARDIAC THROMBOSIS IN ACUTE ANTERIOR MYOCARDIAL INFARCTION: EVALUATION OF HOSPITAL MORTALITY, THROMBOEMBOLISM AND BLEEDING
Authors: Natee Sirinvaravong, Pradhum Ram, Mahek Shah, Shantanu Patil, Brijesh Patel, Shilpkumar Arora, Nilay Patel, Lohit Garg, Sahil Agrawal, Larry Jacobs, Vincent Figueredo
Journal: Journal of the American College of Cardiology (2018)
One in six Croatian medical students wants to emigrate to UK
Authors: Abi Rimmer
Journal: BMJ (2015)

One in six medical students from Croatia wants to emigrate to the United Kingdom, research published online in the Postgraduate Medical Journal has shown.

The researchers surveyed 202 final year medical students at the Zagreb School of Medicine in Croatia in 2013.1 They found that 53% (106) of the students wanted to travel abroad. Of these students 26% (52) …
USE OF OPTICAL COHERENCE TOMOGRAPHY TO DETERMINE THE PATHOGENESIS OF VERY LATE STENT THROMBOSIS IN A NON-COMPLIANT PATIENT WITH PRIOR CORONARY STENTING AND LEFT VENTRICULAR THROMBUS
Authors: Swee Leng Kui, Chee Yang Chin, Khung Keong Yeo
Journal: Journal of the American College of Cardiology (2018)
Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.
Authors: Zuzana Sirotova, Giulia Courthod, Alfredo Tartarone, Orazio Caffo, Francesca Maines, Maurizio Bertuccelli, Franco Morelli, Gianmauro Numico, Pamela Guglielmini, Giuseppe Fornarini, Veronica Prati, Erica Palesandro, Cinzia Ortega, Alessandra Mosca, Stefania Miraglia, Valentina Perrone, Elena Fea, Giacomo Allegrini, Alessandro Mozzicafreddo, Marina Schena
Journal: Journal of Clinical Oncology (2018)

209 Background: Prostate cancer affects mainly elderly patients (pts) that have different comorbidities. AA is a selective androgen synthesis inhibitor that showed the efficacy in either chemotherapy (CT) naive pts or those pretreated with docetaxel. Its oral administration and good tolerability make it a manegeable treatment for elderly mCRPC pts. Methods: We collected retrospectively data regarding mCRPC pts aged ≥75 years treated with AA in 13 Italian Centers since April 2013. The median age was 79 years (r. 75-90) with 48% of pts being octagerians. Post CT pts had more extensive disease, higher baseline PSA and ECOG PS. Nearly all the pts had comorbidities, the most frequent being hypertension present in 146 pts (58%), 43 pts (17%) had diabetes type II. We evaluated duration of the AA treatment, overall response rate (ORR), 50% PSA decline, time to progression (TTP) and overall survival (OS). We reported all toxicities observed. Results: A total of 252 pts ,147 pre treated with docetaxel and 105 chemo naive, were included. Median duration of treatment with AA was 8,6 months in post CT and 11,5 in CT naive pts. ORR was 35,3% in pre docetaxel and 27,4% in post docetaxel group. 64 pts (65%) and 51 pts (46%) obtained 50% PSA reduction in pre and post docetaxel group, respectively. Median TTP was 8,6 in post docetaxel and 11,9 in CT naive pts. We observed a median OS of 13,8 months in post CT group while for CT naive pts data were not yet mature. AA was well tolerated with only 8 pts (3,2%) who discontinued treatment due to toxicity, while in 4 pts (1,6%) temporary dose reductions were performed. The most frequent G3 toxicities were hypertension and liver toxicity with 4 pts (1,6%) and 5 pts (2%), respectively. After progressing on AA, 85 pts (34%) received at least one subsequent treatment. 40 pts (15,9%) are still on treatment with AA. Conclusions: Even if almost all the pts reported comorbidities at AA start and 72 pts (28,6%) had PS ECOG 2, only a small proportion of them discontinued the treatment due to toxicity confirming that AA is well tolerated and efficient treatment also for elderly patients.
Authorship Credit for Large Clinical Trials
Authors: Samuel T. Wilkinson, Gerard Sanacora
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early Strut Coverage in Patients Receiving Drug-Eluting Stents and its Implications for Dual Antiplatelet Therapy
Authors: Seung-Yul Lee, Jung-Sun Kim, Hyuck-Jun Yoon, Seung-Ho Hur, Sang-Gon Lee, Jin Won Kim, Young Joon Hong, Ki-Seok Kim, So-Yeon Choi, Dong-Ho Shin, Chung-Mo Nam, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
Journal: JACC. Cardiovascular imaging (2018)
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis
Authors: Christine M. Halleux, Dennis Falzon, Corinne Merle, Ernesto Jaramillo, Fuad Mirzayev, Piero Olliaro, Karin Weyer
Journal: European Respiratory Journal (2018)

Marketing new medicines before pre-registration clinical trials are complete may sound rash and risky. But when treatment options are scarce in the face of a lethal, transmissible disease the balance tilts in favour of "use" rather than "wait". Such were the conditions under which bedaquiline and delamanid (two new tuberculosis (TB) agents) were introduced a few years ago. This article relates how uncertainties about the safety of these new drugs were handled to enable their use. The World Health Organization has created a central database to improve knowledge on drug-related harms of patients on novel tuberculosis regimens <http://ow.ly/lfVm30ihRcO> The authors wish to thank Michel Vaillant (Luxembourg Institute of Health) for technical support in setting up the global aDSM database, as well as the external experts who participated in the development of the framework (see [[15][1]], annex 1). [1]: #ref-15
Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.
Authors: Shahneen Kaur Sandhu, Andrew Graham Hill, Hui Kong Gan, Michael Friedlander, Mark Voskoboynik, Paula Barlow, Amanda Rose Townsend, James Song, Yun Zhang, Zhirong Shen, Qinzhou Qi, Jayesh Desai
Journal: Journal of Clinical Oncology (2018)

445 Background: Monoclonal antibodies (mAb) against programmed cell death-1 (PD-1) have demonstrated antitumor activity across multiple malignancies. BGB-A317 is a humanized IgG4 mAb with high affinity and binding specificity for PD-1. Previous reports from an ongoing Phase 1A/1B study (NCT02407990) in patients with advanced solid tumors suggested that BGB-A317 was generally well tolerated and had antitumor activity in multiple tumor types. Here, we present the preliminary results from a subset of patients with UC enrolled in this study. Methods: Patients with UC received intravenous BGB-A317 at doses of 2, 5, 10 mg/kg Q2W or Q3W and 200 mg Q3W. Tumor cell (TC) and immune cell (IC) PD-L1 expression was retrospectively assessed with the VENTANA PD-L1 (SP263) assay. Safety and tolerability was assessed by monitoring adverse events (AEs) and antitumor effects were assessed by RECIST v1.1 criteria. Results: As of 8 June 2017, 15 patients with UC (median age, 72 yr [range: 39–79]) received BGB-A317 during phases 1A (n = 8) and 1B (n = 7). All patients were Caucasian and 13 patients were male; the median number of prior systemic anticancer therapies was 1 (range: 0–4). Median duration of treatment was 115 d (range: 27–476); 6 patients remain on treatment. The most common treatment-related AEs (TRAEs) were fatigue (n = 5) and rash (n = 3); grade ≥3 TRAEs included fatigue (n = 1), and hyperglycemia and type 1 diabetes mellitus (T1DM; n = 1). Serious TRAEs occurred in 2 patients (infusion-related reaction [n = 1]; hyperglycemia and T1DM [n = 1]). All patients were evaluable for response assessment. Confirmed complete and partial responses occurred in 1 and 3 patients, respectively, for a response rate of 27%; the disease control rate (CR+PR+SD) was 53%. Nine samples were available for PD-L1 evaluation. Responses were observed in 3 of 6 patients with PD-L1 + tumors (defined as ≥25% TC or IC expressing PD-L1 by IHC) while 1 in 3 patients with PD-L1 – tumors responded. Conclusions: BGB-A317 was generally well tolerated in patients with UC and objective responses were observed in both PD-L1 + and PD-L1 – diseases. BGB-A317 is currently being investigated in China as monotherapy for patients with PD-L1 + UC (CTR20170071). Clinical trial information: NCT02407990.
A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates
Authors: Staci Sabnis, E. Sathyajith Kumarasinghe, Timothy Salerno, Cosmin Mihai, Tatiana Ketova, Joseph J. Senn, Andy Lynn, Alex Bulychev, Iain McFadyen, Joyce Chan, Örn Almarsson, Matthew G. Stanton, Kerry E. Benenato
Journal: Molecular Therapy (2018)
Extending GP services must be tied to available resources, says Stevens
Authors: Abi Rimmer
Journal: BMJ (2015)

Extending GP services to seven days a week was a “legitimate ambition” but should be a phased process that depended on available resources and workforce, the chief executive of the NHS has said.

Speaking at the British Association of Physicians of Indian Origin conference in Birmingham on Sunday 1 November, Simon Stevens said that GP services should be extended, but not on every day of the week.

Krishna Kasaraneni, chair of the BMA’s Equality and Diversity Committee, had asked Stevens whether he thought the push for seven day services in …
Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders
Authors: Raymond K. Walters, Renato Polimanti, Emma C. Johnson, Jeanette N. McClintick, Mark J. Adams, Amy E. Adkins, Fazil Aliev, Silviu-Alin Bacanu, Anthony Batzler, Sarah Bertelsen, Joanna M. Biernacka, Tim B. Bigdeli, Li-Shiun Chen, Toni-Kim Clarke, Yi-Ling Chou, Franziska Degenhardt, Anna R. Docherty, Alexis C. Edwards, Pierre Fontanillas, Jerome C. Foo, Louis Fox, Josef Frank, Ina Giegling, Scott Gordon, Laura M. Hack, Annette M. Hartmann, Sarah M. Hartz, Stefanie Heilmann-Heimbach, Stefan Herms, Colin Hodgkinson, Per Hoffmann, Jouke Jan Hottenga, Martin A. Kennedy, Mervi Alanne-Kinnunen, Bettina Konte, Jari Lahti, Marius Lahti-Pulkkinen, Dongbing Lai, Lannie Ligthart, Anu Loukola, Brion S. Maher, Hamdi Mbarek, Andrew M. McIntosh, Matthew B. McQueen, Jacquelyn L. Meyers, Yuri Milaneschi, Teemu Palviainen, John F. Pearson, Roseann E. Peterson, Samuli Ripatti, Euijung Ryu, Nancy L. Saccone, Jessica E. Salvatore, Sandra Sanchez-Roige, Melanie Schwandt, Richard Sherva, Fabian Streit, Jana Strohmaier, Nathaniel Thomas, Jen-Chyong Wang, Bradley T. Webb, Robbee Wedow, Leah Wetherill, Amanda G. Wills, Jason D. Boardman, Danfeng Chen, Doo-Sup Choi, William E. Copeland, Robert C. Culverhouse, Norbert Dahmen, Louisa Degenhardt, Benjamin W. Domingue, Sarah L. Elson, Mark A. Frye, Wolfgang Gäbel, Caroline Hayward, Marcus Ising, Margaret Keyes, Falk Kiefer, John Kramer, Samuel Kuperman, Susanne Lucae, Michael T. Lynskey, Wolfgang Maier, Karl Mann, Satu Männistö, Bertram Müller-Myhsok, Alison D. Murray, John I. Nurnberger, Aarno Palotie, Ulrich Preuss, Katri Räikkönen, Maureen D Reynolds, Monika Ridinger, Norbert Scherbaum, Marc A. Schuckit, Michael Soyka, Jens Treutlein, Stephanie Witt, Norbert Wodarz, Peter Zill, Daniel E. Adkins, Joseph M. Boden, Dorret I. Boomsma, Laura J. Bierut, Sandra A. Brown, Kathleen K. Bucholz, Sven Cichon, E. Jane Costello, Harriet de Wit, Nancy Diazgranados, Danielle M. Dick, Johan G. Eriksson, Lindsay A. Farrer, Tatiana M. Foroud, Nathan A. Gillespie, Alison M. Goate, David Goldman, Richard A. Grucza, Dana B. Hancock, Kathleen Mullan Harris, Andrew C. Heath, Victor Hesselbrock, John K. Hewitt, Christian J. Hopfer, John Horwood, William Iacono, Eric O. Johnson, Jaakko A. Kaprio, Victor M. Karpyak, Kenneth S. Kendler, Henry R. Kranzler, Kenneth Krauter, Paul Lichtenstein, Penelope A. Lind, Matt McGue, James MacKillop, Pamela A. F. Madden, Hermine H. Maes, Patrik Magnusson, Nicholas G. Martin, Sarah E. Medland, Grant W. Montgomery, Elliot C. Nelson, Markus M. Nöthen, Abraham A. Palmer, Nancy L. Pedersen, Brenda W. J. H. Penninx, Bernice Porjesz, John P. Rice, Marcella Rietschel, Brien P. Riley, Richard Rose, Dan Rujescu, Pei-Hong Shen, Judy Silberg, Michael C. Stallings, Ralph E. Tarter, Michael M. Vanyukov, Scott Vrieze, Tamara L. Wall, John B. Whitfield, Hongyu Zhao, Benjamin M. Neale, Joel Gelernter, Howard J. Edenberg, Arpana Agrawal
Journal: Nature Neuroscience (2018)
Unveiling skin macrophage dynamics explains both tattoo persistence and strenuous removal
Authors: Anna Baranska, Alaa Shawket, Mabel Jouve, Myriam Baratin, Camille Malosse, Odessa Voluzan, Thien-Phong Vu Manh, Frédéric Fiore, Marc Bajénoff, Philippe Benaroch, Marc Dalod, Marie Malissen, Sandrine Henri, Bernard Malissen
Journal: The Journal of Experimental Medicine (2018)

Here we describe a new mouse model that exploits the pattern of expression of the high-affinity IgG receptor (CD64) and allows diphtheria toxin (DT)-mediated ablation of tissue-resident macrophages and monocyte-derived cells. We found that the myeloid cells of the ear skin dermis are dominated by DT-sensitive, melanin-laden cells that have been missed in previous studies and correspond to macrophages that have ingested melanosomes from neighboring melanocytes. Those cells have been referred to as melanophages in humans. We also identified melanophages in melanocytic melanoma. Benefiting of our knowledge on melanophage dynamics, we determined the identity, origin, and dynamics of the skin myeloid cells that capture and retain tattoo pigment particles. We showed that they are exclusively made of dermal macrophages. Using the possibility to delete them, we further demonstrated that tattoo pigment particles can undergo successive cycles of capture-release-recapture without any tattoo vanishing. Therefore, congruent with dermal macrophage dynamics, long-term tattoo persistence likely relies on macrophage renewal rather than on macrophage longevity.
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
Authors: Scott N Gettinger, Anna Wurtz, Sarah B Goldberg, David Rimm, Kurt Schalper, Susan Kaech, Paula Kavathas, Anne Chiang, Rogerio Lilenbaum, Daniel Zelterman, Katerina Politi, Roy S Herbst
Journal: Journal of Thoracic Oncology (2018)
When is the best time to sit the MRCS examination?
Authors: Duncan Scrimgeour, Jennifer Cleland, Amanda Lee, Peter A Brennan
Journal: BMJ (2017)

<b>Duncan Scrimgeour, Jennifer Cleland, Amanda Lee,</b> and <b>Peter Brennan</b> shed some light on when to sit the Intercollegiate Membership of the Royal College of Surgeons (MRCS) examination
Office-Based Screening for Dementia in Parkinson Disease
Authors: Benjamin K. Dawson, Seyed-Mohammad Fereshtehnejad, Julius B. M. Anang, Takashi Nomura, Silvia Rios-Romenets, Kenji Nakashima, Jean-François Gagnon, Ronald B. Postuma
Journal: JAMA Neurology (2018)

<h3>Importance</h3> Parkinson disease dementia dramatically increases mortality rates, patient expenditures, hospitalization risk, and caregiver burden. Currently, predicting Parkinson disease dementia risk is difficult, particularly in an office-based setting, without extensive biomarker testing. <h3>Objective</h3> To appraise the predictive validity of the Montreal Parkinson Risk of Dementia Scale, an office-based screening tool consisting of 8 items that are simply assessed. <h3>Design, Setting, and Participants</h3> This multicenter study (Montreal, Canada; Tottori, Japan; and Parkinson Progression Markers Initiative sites) used 4 diverse Parkinson disease cohorts with a prospective 4.4-year follow-up. A total of 717 patients with Parkinson disease were recruited between May 2005 and June 2016. Of these, 607 were dementia-free at baseline and followed-up for 1 year or more and so were included. The association of individual baseline scale variables with eventual dementia risk was calculated. Participants were then randomly split into cohorts to investigate weighting and determine the scale's optimal cutoff point. Receiver operating characteristic curves were calculated and correlations with selected biomarkers were investigated. <h3>Main Outcomes and Measures</h3> Dementia, as defined by Movement Disorder Society level I criteria. <h3>Results</h3> Of the 607 patients (mean [SD] age, 63.4 [10.1]; 376 men [62%]), 70 (11.5%) converted to dementia. All 8 items of the Montreal Parkinson Risk of Dementia Scale independently predicted dementia development at the 5% significance level. The annual conversion rate to dementia in the high-risk group (score, &gt;5) was 14.9% compared with 5.8% in the intermediate group (score, 4-5) and 0.6% in the low-risk group (score, 0-3). The weighting procedure conferred no significant advantage. Overall predictive validity by the area under the receiver operating characteristic curve was 0.877 (95% CI, 0.829-0.924) across all cohorts. A cutoff of 4 or greater yielded a sensitivity of 77.1% (95% CI, 65.6-86.3) and a specificity of 87.2% (95% CI, 84.1-89.9), with a positive predictive value (as of 4.4 years) of 43.90% (95% CI, 37.76-50.24) and a negative predictive value of 96.70% (95% CI, 95.01-97.85). Positive and negative likelihood ratios were 5.94 (95% CI, 4.08-8.65) and 0.26 (95% CI, 0.17-0.40), respectively. Scale results correlated with markers of Alzheimer pathology and neuropsychological test results. <h3>Conclusions and Relevance</h3> Despite its simplicity, the Montreal Parkinson Risk of Dementia Scale demonstrated predictive validity equal or greater to previously described algorithms using biomarker assessments. Future studies using head-to-head comparisons or refinement of weighting would be of interest.
Effect modification of perinatal exposure to air pollution and childhood asthma incidence
Authors: Éric Lavigne, Marc-André Bélair, Daniel Rodriguez Duque, Minh T. Do, David M. Stieb, Perry Hystad, Aaron van Donkelaar, Randall V. Martin, Daniel L. Crouse, Eric Crighton, Hong Chen, Richard T. Burnett, Scott Weichenthal, Paul J. Villeneuve, Teresa To, Jeffrey R. Brook, Markey Johnson, Sabit Cakmak, Abdool S. Yasseen, Mark Walker
Journal: European Respiratory Journal (2018)

Perinatal exposure to ambient air pollution has been associated with childhood asthma incidence, however, less is known regarding the potential effect modifiers in this association. We examined whether maternal and infant characteristics modified the association between perinatal exposure to air pollution and development of childhood asthma.761 172 births occurring between 2006 and 2012 were identified in the province of Ontario, Canada. Associations between exposure to ambient air pollutants and childhood asthma incidence (up to age 6) were estimated using Cox regression models.110,981 children with asthma were identified. In models adjusted for postnatal exposures, second trimester exposures to particulate matter with a diameter ≤2.5 μm (PM
Put more money into general practice to protect patient services, say GPs
Authors: Abi Rimmer
Journal: BMJ (2014)

A greater proportion of the NHS budget must go into general practice to protect services for patients, GPs have said.

Delegates at the BMA’s local medical committee (LMC) conference in York this week unanimously supported a motion saying that there would “no longer be a sustainable NHS unless the decline in general practice is urgently addressed.”

The motion said that “general practice is the most cost effective part of the NHS” and demanded …